Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
BACKGROUND
The aim of this work was to compare the suitability of different pharmacodynamic models for PK-PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension.


METHODS
A "shunt" microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg(-1)). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified E(max) model.


RESULTS
No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK-PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK-PD parameters, linear and E(max) model did not permit an accurate PK-PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified E(max) model allows both a precise and accurate estimation of PK-PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK-PD parameters estimated for the hypotensive response.


CONCLUSIONS
Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK-PD parameters estimation by using the linear and classical E(max) model depends on the magnitude of concentration-effect curve covered in the study. Conversely, the modified E(max) model allowed both a precise and accurate estimation of PK-PD parameters, suggesting that the modified E(max) pharmacodynamic model is the most suitable for verapamil PK-PD modeling.
Bertera
Facundo M
FM
Cátedra de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, (C1113AAD) Buenos Aires, Argentina.
Mayer
Marcos A
MA
Opezzo
Javier A W
JA
Taira
Carlos A
CA
Höcht
Christian
C
D000818:Animals; D001011:Aorta / Q000601:surgery; D001017:Aortic Coarctation / Q000150:complications / Q000601:surgery; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects; D006978:Hypertension, Renovascular / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D014700:Verapamil / Q000493:pharmacokinetics*
D002121:Calcium Channel Blockers; D014700:Verapamil